by admin | Feb 21, 2022 | News
BiOrion Technologies BV has raised additional funding from one of its founders for a clinical phase 2 diagnostic-imaging program in cardiac fibrosis patients. BiOrion Technologies BV (BiOrion), a biopharmaceutical drug discovery company, develops products for...
by admin | Sep 30, 2020 | News
BiOrion Technologies announced today that a first fibrosis patient has been enrolled in the first-in-human PET imaging study with 68-Gallium labeled PDGF beta receptor binding bicyclic peptide BOT5035. Herman Steen, CEO of BiOrion, “The enrollment of the first patient...
by admin | Mar 4, 2019 | News
BiOrion has raised funding from a consortium of two existing and one new investor for its further clinical validation programs in fibrosis and fibrotic cancers. BiOrion, a biopharmaceutical drug discovery company, develops products for the diagnosis and treatment of...
by admin | Dec 14, 2017 | News
An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac fibrosis imaging program is awarded to BiOrion Technologies BV. The grant will be used for the preparation and execution of a clinical phase 0 imaging study in cardiac fibrosis patients and the...
by admin | Sep 26, 2017 | News
The EUROSTARS grant of a EUR 1.8 million fibrosis imaging program is awarded to a multidisciplinary consortium including BiOrion Technologies BV, Zealand Pharma A/S and Akademiska Sjukhuset, PET Centre, University Uppsala. EUROSTARS is a joint program between EUREKA...
